Global Oligonucleotide API Market to Grow with a CAGR of ~10% During 2024-2036; Market to Grow on Account of Rising Investments in Drug Discovery
Research Nester published a report titled “Oligonucleotide API Market: Global Demand Analysis & Opportunity Outlook 2036” which delivers detailed overview of the global oligonucleotide API market in terms of market segmentation by product type, marketing status, end user, and by region.
Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.
Request Report Sample@
https://www.researchnester.com/sample-request-4308
The global oligonucleotide API market is anticipated to grow with a CAGR of ~10% during the forecast period, i.e., 2024-2036. The market is segmented by end user into pharmaceutical companies and biotechnology companies. Out of these, the pharmaceutical companies segment is anticipated to garner the largest revenue by the end of 2031. Growing and versatile usage of oligonucleotides in the pharmaceutical industry is expected to fuel segment growth. The pharmaceutical industry has recognized the benefits of oligonucleotides in a variety of ways, such as antisense oligonucleotides, splice-switching oligonucleotides, microRNAs, and immunostimulatory oligonucleotides.
The global oligonucleotide API market is estimated to garner revenue of USD 5 Billion by the end of 2036, up from revenue of USD 2 Billion in the year 2021. Growing cases of cancer and other neurological diseases, increasing spending on healthcare, rising per capita income, R&D initiatives by the government towards drug discovery, and big science projects are some of the major factors anticipated to drive the growth of the market during the forecast period.
Geographically, the global oligonucleotide API market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Out of these, the market in North America is projected to garner the largest revenue by the end of 2031. Investments in research and development of oligonucleotide therapies are anticipated to drive the market in region during the forecast period. Additionally, oligonucleotide API sales in the region are expected to grow owing to increased healthcare spending and enhanced healthcare services. Healthcare services accounted for 19.7% of GDP in the United States in 2020, or USD 4.1 trillion, according to a recent report by the Centers for Medicare & Medicaid Services.
The research is global in nature and covers detailed analysis on the market in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa). In addition, analysis comprising market size, Y-O-Y growth & opportunity analysis, market players’ competitive study, investment opportunities, demand for future outlook etc. has also been covered and displayed in the research report.
Increasing Prevalence of Cancer and Neurodegenerative Diseases to Drive the Market Growth
According to the National Cancer Institute, in 2020, cancer diagnoses in the United States totaled 1,806,590, and deaths from cancer numbered 606,520.
A growing number of cancer cases is driving the demand for advanced testing procedures. Also, neurodegenerative diseases require a personalized treatment approach. Conventional medicine has a number of limitations, as a result, oligonucleotide APIs are being extensively studied. Owing to this factor global oligonucleotide API market growth is anticipated to grow during the forecast period.
However, mandatory guidelines for good manufacturing practices and product licensing are expected to operate as key restraint to the growth of global oligonucleotide API market over the forecast period.
This report also provides the existing competitive scenario of some of the key players of the global oligonucleotide API market which includes company profiling of Ionis Pharmaceuticals, Inc., Jazz Pharmaceuticals plc, Biogen, Sarepta Therapeutics, Alnylam Pharmaceuticals, Inc., Corden Pharma GmbH, Dynavax Technologies, GE Healthcare Life Sciences, and Nitto Denko Avecia. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global oligonucleotide API market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
Access our detailed report at:
https://www.researchnester.com/reports/oligonucleotide-api-market/4308
Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties.
Contact for more Info:
AJ Daniel
Email: info@researchnester.com
U.S. Phone: +1 646 586 9123
U.K. Phone: +44 203 608 5919